CROWN HOLDINGS, INC. (CCK) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-07

Key Insights

Garry Kevin, VP & Corporate Controller, acquired 900 restricted shares at zero cost on 04/15/2026, indicating a standard equity compensation grant rather than open market purchase.
The restricted shares vest over three years in equal tranches (300 shares each on May 14, 2027, May 15, 2028, and May 14, 2029), representing typical retention-focused executive compensation structure.
The transaction represents modest insider ownership accumulation with total beneficial ownership of 4,500 shares post-transaction, suggesting limited personal capital deployment by this mid-level corporate officer.
No derivative securities or options are involved in this filing, indicating this is purely a time-vested restricted stock grant with no leveraged upside potential for the reporting person.

Want the newest filings?

This analysis covers the filing from 2026-05-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-07

Director Michael P. Doss acquired 417 shares of deferred stock on 05/06/2026, valued at approximately $41,265 based on the $99.038 exercise price, representing a modest insider equity position increase.
The deferred stock acquisition is non-dilutive compensation that converts to cash upon cessation of director duties, indicating standard director compensation practices rather than a signal of insider confidence in near-term stock appreciation.
This routine director compensation transaction represents minimal trading activity with no material implications for ownership concentration or company valuation, typical of periodic equity grants to board members.

Filed: 2026-05-07

Director Richard H. Fearon acquired 417 shares of CCK on 05/06/2026 at approximately $99.04 per share, representing a direct purchase of roughly $41,300 in company stock.
The transaction includes indirect beneficial ownership of 16 shares through the Fearon Family Trust, bringing total beneficial ownership to 12,478 shares, indicating meaningful personal investment alignment with shareholders.
This insider purchase by a director during normal trading conditions suggests confidence in the company's valuation and future prospects, though the modest transaction size limits its significance as a major bullish signal.

Filed: 2026-05-07

Director Andrea J. Funk acquired 417 shares of CCK common stock on 05/06/2026 at $99.038 per share, increasing her direct beneficial ownership to 17,527 shares, indicating insider confidence in the company's valuation.
This is a modest insider purchase representing approximately $41,306 in investment, suggesting a measured rather than aggressive accumulation pattern by this director-level insider.
The transaction was executed through a standard purchase mechanism (not part of a Rule 10b5-1 plan), indicating a discretionary buy decision rather than a pre-arranged trading program.

Filed: 2026-05-07

Director Stephen J. Hagge acquired 417 shares of CCK common stock on 05/06/2026 at $99.038 per share, increasing his direct beneficial ownership to 11,301 shares, suggesting confidence in the company's valuation.
The acquisition was executed through a single transaction rather than multiple purchases, indicating a deliberate investment decision by an insider with board-level responsibility.
No derivative securities transactions were reported, and the filing shows no offsetting stock dispositions, indicating net bullish positioning by the director during this period.

Filed: 2026-05-07

Director B. Craig Owens acquired 417 shares of CCK common stock on 05/06/2026 at $99.038 per share, totaling approximately $41,313 in insider buying activity.
Post-transaction, Owens holds 11,680 shares directly and maintains an additional 2,000 shares indirectly through The B Craig Owens Rev Trust, demonstrating sustained confidence in the company.
The transaction was executed on 05/06/2026 and filed the following day (05/07/2026), indicating timely insider reporting compliance with SEC regulations.

Filed: 2026-05-07

Director Angela M. Snyder acquired 417 shares of CCK common stock on 05/06/2026 at $99.038 per share, bringing her total beneficial ownership to 6,805 shares, indicating insider confidence in the company at current valuation levels.
The transaction was executed as a direct purchase rather than through any derivative securities or option exercises, suggesting a straightforward market purchase that demonstrates personal investment conviction.
As a Director-level insider, this acquisition signals management's positive outlook on Crown Holdings, though the modest share count (417 shares) represents a relatively small capital commitment relative to typical director compensation and holdings patterns.

Filed: 2026-05-07

Director Caesar F. Sweitzer acquired 417 shares of CCK common stock on 05/06/2026 at $99.038 per share, representing a direct purchase totaling approximately $41,263.
Following this transaction, Sweitzer's total beneficial ownership increased to 24,877 shares held directly, indicating continued confidence in the company by a board member.
The acquisition was executed through a single transaction rather than a Rule 10b5-1 trading plan, suggesting a discretionary purchase decision rather than a pre-arranged program.

Filed: 2026-05-07

Director Marsha C. Williams purchased 417 shares of CCK common stock on 05/06/2026 at $99.038 per share, increasing her direct beneficial ownership to 7,763 shares, indicating confidence in the company's valuation.
The transaction represents a modest insider buy of approximately $41,300 in aggregate value, suggesting measured confidence rather than a major accumulation or conviction-driven purchase by the director.
No derivative securities activity is reported in this filing, indicating this was a straightforward common stock acquisition with no options, warrants, or convertible securities involved in the transaction.

Filed: 2026-05-07

Director Wilson Dwayne Andree acquired 417 shares of deferred stock on 05/06/2026 at an implied value of $99.038 per share, indicating insider confidence in Crown Holdings' valuation.
The deferred stock acquisition is relatively modest in size, representing a routine equity compensation grant rather than a significant discretionary purchase, which limits the strength of the bullish signal.
Andree's beneficial ownership increased to 3,865 shares following this transaction, with the deferred stock vesting as cash upon cessation of directorship, a standard director compensation mechanism.

Filed: 2026-04-21

EVP & COO John M. Rost received 1,811 restricted stock units as compensation on 04/17/2026, with a mix of time-vested (623 shares) and performance-based (1,188 shares) components, indicating continued equity-based incentive alignment with company performance.
Performance-based vesting is significant with 557 shares tied to Total Shareholder Return versus peers and 631 shares tied to Return on Invested Capital metrics, suggesting management compensation is directly linked to operational efficiency and shareholder value creation.
The grant carries no purchase price ($0), consistent with restricted stock compensation practice, and represents standard annual equity award for a C-suite executive at a large industrial company.
Rost's total direct beneficial ownership increased to 19,682 shares from the transaction, with an additional 298 shares held indirectly through the 401(k) plan, showing modest equity stake relative to his executive position.

Filed: 2026-04-15

The reporting person, Timothy J. Donahue, who is the President and CEO of Crown Holdings, Inc. (CCK), has sold 7,500 shares of the company's common stock on April 15, 2026 at a price of $106.85 per share.
Donahue still holds a significant position in the company, with 451,070 shares owned directly and an additional 784 shares held indirectly through a 401(k) plan.
The sale was made pursuant to a Rule 10b5-1 trading plan, which suggests it was part of a pre-planned strategy rather than a reaction to specific events.

Filed: 2026-04-09

The reporting person, Timothy J. Donahue, who is the President and CEO of Crown Holdings, Inc., sold 7,500 shares of the company's common stock on April 8, 2026 for $105 per share.
Donahue continues to hold a significant number of shares (458,570) directly, as well as an additional 784 shares through the company's 401(k) plan.
The transaction was made pursuant to a 10b5-1 trading plan, indicating it was part of a pre-arranged stock disposition strategy.

Filed: 2026-03-02

The reporting person, Adam J. Dickstein, acquired 952 additional performance-based restricted shares of CROWN HOLDINGS, INC. (CCK) stock on February 26, 2026, indicating the company's Return on Invested Capital (ROIC) target was met at 120% payout.
Dickstein also disposed of 2,485 shares of CCK stock on the same date, likely for tax withholding purposes related to the vesting of the restricted shares.
The insider transactions suggest Dickstein, who serves as SVP, General Counsel and Secretary, remains confident in CCK's performance and is aligning his personal holdings with the company's long-term success.

Filed: 2026-03-02

The reporting person, Djalma Novaes Jr., acquired 1,016 additional performance-based restricted shares of Crown Holdings, Inc. common stock that vested on February 26, 2026, indicating continued ownership and alignment with the company's performance.
The reporting person also sold 2,399 shares to cover tax withholding obligations, suggesting routine portfolio management rather than significant selling activity.
The vesting of performance-based shares aligns with the company's reported Return on Invested Capital (ROIC) performance, providing insight into the company's operational efficiency.

Other reports for CROWN HOLDINGS, INC.

Quarterly Report Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.